Skip to content

The Interventional Study on the Improvement of Microcirculation in Diabetic Foot Patients by water-filtered infrared-A (wIRA)

The Interventional Study on the Improvement of Microcirculation in Diabetic Foot Patients by water-filtered infrared-A (wIRA)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600125298
Enrollment
Unknown
Registered
2026-05-25
Start date
2025-08-30
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic foot, Wagner Grade 0-3

Interventions

Intervention group:Wate filtered infrared A + routine medical care

Sponsors

China-Japan Friendship Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Age between 18 and 80 years. 2.Meets the clinical diagnostic criteria for diabetic foot (DF) according to the 2023 IWGDF guidelines, with Wagner grade 0–3. 3. No contraindications to water-filtered infrared-A (wIRA) (no photosensitivity, cataracts, glaucoma, etc.); 4.Has obtained informed consent from the participant, or from a family member/guardian, and signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1.Patients with unstable blood glucose control, glycated hemoglobin (HbA1c) >=12%. 2.Patients with severe hypertension (resting blood pressure >=160/120 mmHg). 3.Pregnant women. 4.Patients with photosensitivity or autoimmune diseases such as systemic lupus erythematosus. 5.Patients with heat sensitivity or other conditions unsuitable for thermotherapy. 6.Patients with bleeding tendencies, coagulation disorders, or deep vein thrombosis. 7.Patients taking immunosuppressants, corticosteroids, or other medications that may affect wound healing. 8.Patients with severe comorbidities such as malignant tumors or acute cardiovascular/cerebrovascular events. 9.Patients with dermatological diseases, acute purulent infections, or other serious conditions that may affect study outcomes. 10.Patients unable to comply with the study protocol.

Design outcomes

Primary

MeasureTime frame
Local microcirculatory perfusion changes;

Secondary

MeasureTime frame
Patient compliance and treatment safety;Vascular endothelial function and markers of endothelial injury;Plantar pressure and scanning information;Clinical symptom improvement;

Countries

China

Contacts

Public ContactYangxi Li

China-Japan Friendship Hospital

chyx_1983@163.com+86 10 8420 5718

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026